143 related articles for article (PubMed ID: 14562117)
1. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial.
Buesche G; Hehlmann R; Hecker H; Heimpel H; Heinze B; Schmeil A; Pfirrmann M; Gomez G; Tobler A; Herrmann H; Kappler M; Hasford J; Buhr T; Kreipe HH; Georgii A
Leukemia; 2003 Dec; 17(12):2444-53. PubMed ID: 14562117
[TBL] [Abstract][Full Text] [Related]
2. Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia.
Buesche G; Freund M; Hehlmann R; Georgii A; Ganser A; Hecker H; Heimpel H; Fonatsch C; Heinze B; Pfirrmann M; Holgado S; Schmeil A; Tobler A; Hasford J; Buhr T; Kreipe HH;
Leukemia; 2004 Sep; 18(9):1460-7. PubMed ID: 15284854
[TBL] [Abstract][Full Text] [Related]
3. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.
Berger U; Maywald O; Pfirrmann M; Lahaye T; Hochhaus A; Reiter A; Hasford J; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Hehlmann R;
Leukemia; 2005 Jun; 19(6):984-9. PubMed ID: 15830009
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H;
Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239
[TBL] [Abstract][Full Text] [Related]
5. Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
Berger U; Engelich G; Maywald O; Pfirrmann M; Hochhaus A; Reiter A; Metzgeroth G; Gnad U; Hasford J; Heinze B; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Hehlmann R;
Leukemia; 2003 Sep; 17(9):1820-6. PubMed ID: 12970782
[TBL] [Abstract][Full Text] [Related]
6. [Recent progress in therapy for chronic myelogenous leukemia].
Urabe A
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1066-73. PubMed ID: 9239158
[TBL] [Abstract][Full Text] [Related]
7. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.
J Natl Cancer Inst; 1997 Nov; 89(21):1616-20. PubMed ID: 9362160
[TBL] [Abstract][Full Text] [Related]
8. [Chronic myelogenous leukemia with long-term hypoplasia induced by alpha-interferon and hydroxyurea].
Motomura S; Sakai R; Tomita N; Fujimaki K; Hattori M; Fujisawa S; Mohri H; Takahashi N; Maruta A; Kodama F; Okubo T
Rinsho Ketsueki; 1998 Apr; 39(4):302-7. PubMed ID: 9597898
[TBL] [Abstract][Full Text] [Related]
9. Therapy-related changes of CD20+ and CD45RO+ lymphocyte subsets in chronic myeloid leukemia (CML): an immunohistochemical and morphometric study on sequential trephine biopsies of the bone marrow.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Cvetanovska G; Blum N; Schaefer HE
Mod Pathol; 2000 Aug; 13(8):888-96. PubMed ID: 10955456
[TBL] [Abstract][Full Text] [Related]
10. Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Bundschuh S; Biermann T; Roessler G; Wasmus M; Diehl V; Zankovich R; Schaefer HE
Am J Clin Pathol; 2000 Jul; 114(1):57-65. PubMed ID: 10884800
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
[TBL] [Abstract][Full Text] [Related]
12. [Chronic myeloid leukemia].
Hehlmann R
Ther Umsch; 1996 Feb; 53(2):82-7. PubMed ID: 8629268
[TBL] [Abstract][Full Text] [Related]
13. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia.
Buesche G; Ganser A; Schlegelberger B; von Neuhoff N; Gadzicki D; Hecker H; Bock O; Frye B; Kreipe H
Leukemia; 2007 Dec; 21(12):2420-7. PubMed ID: 17805334
[TBL] [Abstract][Full Text] [Related]
14. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia.
Kantarjian HM; Talpaz M
Semin Oncol; 1994 Dec; 21(6 Suppl 14):8-13. PubMed ID: 7992099
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Hochhaus A; Heinze B
Blood; 1994 Dec; 84(12):4064-77. PubMed ID: 7994025
[TBL] [Abstract][Full Text] [Related]
18. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
20. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
